Cano-Soldado P, Gorraitz E, Errasti-Murugarren E, Casado FJ, Lostao MP, Pastor-Anglada M. Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket.
hCNT1; hCNT3; nucleoside transport; nucleoside-derived drugs; polymorphism CHEMOTHERAPY based on the use of nucleoside analogs relies on the ability of target cells to transport drugs across the plasma membrane. Two gene families have been identified as responsible for the uptake of natural nucleosides in mammals, SLC28 and SLC29, encoding concentrative nucleoside transporter (CNT1-3) and equilibrative nucleoside transporter (ENT1-4) proteins, respectively. Most nucleoside-derived drugs are also efficiently translocated by nucleoside transporter (NT) proteins (29, 34) .
Human CNT1 (hCNT1, encoded by the SLC28A1 gene) translocates pyrimidine-nucleosides and pyrimidine-drug derivatives through a 1:1 Na ϩ -nucleoside concentrative mechanism. This stoichiometry is shared by hCNT2, but not hCNT3, which shows a 2:1 Na ϩ -nucleoside stoichiometry (33) . Human CNT1 is broadly expressed, and its apical expression in renal and intestinal epithelial cells suggests a putative role in (re)absorption processes, thus making hCNT1 a major candidate for determining nucleoside-derived drug pharmacokinetics (29) . In fact, hCNT1 is known to be a high-affinity fluoropyrimidine transporter capable of increasing sensitivity to halogenated drugs such as 5=-deoxy-5-fluorouridine (5=-DFUR) and gemcitabine (2=,2=-difluorodeoxycytidine) (13, 21, 25) . Moreover, hCNT1 expression can compensate for the loss of equilibrative nucleoside transporter function in cell systems (2) , which may mimic some cases of breast cancer (24) . Therefore, overexpression or retention of hCNT1 expression alone might be sufficient for nucleoside-derived drugs to exert their cytotoxic actions in tumors, even if they have lost hENT expression and related activities. In addition to its role as a drug transporter, hCNT1 expression by itself appears to be linked to disease prognosis, at least in some gynecological tumors (12) .
An additional element determining drug response is transporter genetic variability, which could even explain patient heterogeneity in drug pharmacokinetics (5, 16, 19) . For hCNT1, 58 single nucleotide polymorphisms (SNPs) have been identified (14) showing the highest frequency (SNP/100 bp) among 24 membrane transporters analyzed in 2003 by Leabman et al. (22) . Of the 58 SNPs identified, 26 were found in coding regions and 13 of these were nonsynonymous changes. In addition, two insertion and deletion mutations were identified in hCNT1. Functional analysis of hCNT1 variants identified two nonfunctional proteins as deduced from a lack of thymidine transport activity when measured at a single substrate concentration. One is a frameshift mutation that presumably results in a truncated protein, whereas the other nonfunctional hCNT1 variant results from a change of a highly conserved serine residue in position 546 to proline. To our knowledge, hCNT1S546P is the only apparently nonfunctional natural variant protein in the NT families due to a single amino acid change substitution (10) . Nevertheless, particular polymorphisms can differentially affect substrate recognition and translocation, as we recently reported for the hCNT3C602R transporter (8) . This particular variant shows impaired binding of one of two sodium ions normally transported by either one purine or one pyrimidine nucleoside per translocation cycle. Importantly, this variant also shows a selective loss of substrate binding affinity, which is highly variable among nucleosidederived drugs. Thus, whereas affinity for natural nucleosides appears to be unaffected, the interaction affinity for some nucleoside analogs is decreased more than 10-fold, resulting in the inability of this transporter variant to efficiently translocate some substrates (9) .
In this study we wanted to gain further insights into the molecular mechanisms resulting in the apparent loss of function of the hCNT1S546P variant. We extended the initial observation that hCNT1S546P could not translocate thymidine to other nucleosides and nucleoside-derived drugs. Appropriate endoplasmic reticulum export and localization of the transporter variant into the plasma membrane as well as its sodiumbinding properties have also been studied in detail. Moreover, the comparative analysis of the homologous residue in hCNT3 provides further insight into the sodium-binding properties of this family of transporter proteins.
MATERIALS AND METHODS
Cell culture and transfection. Human cervix carcinoma cells (HeLa) and Madin-Darby canine kidney cells (MDCK) were routinely maintained at 37°C/5% CO2 in Dulbecco's modified Eagle's medium (Lonza Verviers SPRL, Verviers, Belgium) supplemented with 10% fetal bovine serum (vol/vol) (GIBCO-BRL, Grand Island, NY), 2 mM glutamine, and a mixture of antibiotics (100 U penicillin, 0.1 mg/ml streptomycin, and 0.25 mg/ml fungizone). Both HeLa and MDCK cells were transiently transfected with a pcDNA3 vector incorporating hCNT1 cDNA, cloned from human fetal liver (GenBank accession number U62966) (25) , and a pcDNA3.1-hCNT3 plasmid cloned from a normal portion of a kidney bearing a renal carcinoma and removed at surgery, according to the ethics review board of the Institutd=Uro-logia, Nefrologia i Andrologia-Fundació Puigvert (IUNA) (8) . Neither cell line showed any endogenous activity due to concentrative nucleoside transporters. Other plasmids used in this issue were generated from pcDNA3-hCNT1 and pcDNA3.1-hCNT3 templates. The transfection in cells maintained as monolayer cultures was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and following the manufacturer's protocol. MDCK cells were plated on transwell plates (12 mm diameter, 0.3 m pore; Costar; Corning Life Sciences, Acton, MA) and transfected as described previously Harris et al. (15) .
Plasmid construction and site-directed mutagenesis. Green fluorescence protein (GFP)-fused hCNT1 was generated using pEGFP-C1 (Clontech, Mountain View, CA) and the hCNT1 insert. This insert was obtained by introducing EcoRI and SmaI restriction sites at the end of the hCNT1 cDNA sequence via extended primers EcoRI: 5=-ATCG-GAATTCCTGGGACATGGAGAACGAC-3= and SmaI: 5=-AAAAC-CCGGGGGAGAACAGCCC-3=. Both pEGFP-C1 and the hCNT1 insert were double digested with EcoRI and SmaI and ligated with the T4 DNA ligase (Promega, Madison, WI). GFP-fused hCNT3 protein was subcloned between PstI and HindIII sites (8) . The QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used to introduce the desired mutations in hCNT1 and hCNT3 cDNAs. The pcDNA3-, GFPfused hCNT1, and pcDNA3.1-, GFP-fused hCNT3 were used as templates. The S546P, S546A, S546T, S546C, S546R, and S546del substitutions were introduced into hCNT1 using a compatible reverse primer and as forward primers; hCNT1S546P: 5=-GGATTTGCCAAC-TTCAGCCCCATTGGGATCATGCTGGGAGG-3=, hCNT1S546A: 5=-GGATTTGCCAACTTCAGCGCCATTGGGATCATGCTGGGAGG-3=, hCNT1S546T: 5=-GGATTTGCCAACTTCAGCACCATTGGGAT-CATGCTGGGAGG-3=, hCNT1S546C: 5=-GGATTTGCCAACT-TCAGCTGCATTGGGATCATGCTGGGAGG-3=, hCNT1S546R: 5=-GGATTTGCCAACTTCAGCCGCATTGGGATCATGCTGGGAGG-3=, and hCNT1S546del: 5=-GGATTTGCCAACTTCAGCATTGGGAT-CATGCTGGGAGG-3=.
The S568P substitution was introduced into hCNT3 using a forward primer 5=-GGTTTTGCCAATATCGGGCCCCTAGGAATCGTGATC-GGCG-3=. Subsequently, the constructs generated were verified by DNA sequencing (BigDye Terminator v3.1, Applied Biosystems, Foster City, CA) in both directions and later used for transient transfection.
Genotyping. Genomic DNA obtained from oral mucosa of 200 people with their informed consent and isolated with the use of a commercial kit (QIAGEN, Hilden, Germany) was a generous gift from Dr. Dolors Colomer (Hospital Clínic, IDIBAPS, Barcelona, Spain). Genotyping was performed using allele-specific locked nucleic acid dual-labeled fluorogenic probes labeled with FAM and HEX reporters. Primers and probes were generated by Sigma-Proligo design service. Primers: forward 5=-TGAAGTCCTCACGACGTTTG-3=; reverse 5=-AGACTCTCCTAGACACTGGTGAG-3=; Probes: FAM 5=-GϩGϩ AGCTGAAϩGTTϩGGCAA-3= BHQ1; HEX 5=-AATϩGϩGϩ GGCTGAAGTTϩGG-3= BHQ1 The plus sign before the bases indicates an locked nucleic acid base. Amplification reactions were performed in optical 384-well plates using 20 ng of DNA, primers (400 nM), and probes (100 nM). After amplification, fluorescence was read in an ABI7900HT sequence detector (Applied Biosystems).
Nucleoside and nucleobase transport assay. Uptake rates were measured by incubating cell monolayers in an uptake buffer (in mM: 5.4 KCl, 1.8 CaCl 2, 1.2 MgSO4, and 10 HEPES), supplemented with either sodium or sodium-free (choline chloride) (137 mM), in which the labeled nucleoside or nucleobase was added at a final concentration of 1 M (specific activity 1 Ci/nmol). Incubations were stopped by rapid aspiration of the uptake buffer followed by immediate washing with a cold stop solution, as previously described (7) . Concentration dependence of Na ϩ -dependent uridine uptake was measured with varied concentrations of nucleoside (0 -250 M), whereas Hill coefficients for Na ϩ activation of nucleoside transport were calculated by uridine uptake using transport medium containing 0 -100 mM NaCl using choline chloride to maintain isosmolality. Transwell transport experiments were performed seeding MDCK cells (1.9 ϫ 10 5 ) on 12-well polycarbonate transwell filter inserts (Corning Costar; 12 mm diameter, 0.3 m pore), and uptake rates were measured as previously described (11) . To ensure that cells had polarized and formed tight junctions, transport experiments were conducted when the transepithelial electrical resistance values (measured by millicell-ERS; Millipore, Bedford, MA) reached 300 -500 ⍀·cm 2 in representative wells. Sodium-22 uptake assays were optimized for specific activity and transport rate by using a saturating concentration of thymidine (200 M), a sodium concentration of 10 mM (3-4 times the Na ϩ K0.5, 2 Ci/ml) and ouabain 1 mM (to inhibit the Na ϩ -K ϩ pump). Cells were incubated with the transport buffer, and after 6 or 12 min the transport was terminated by washing in an excess of chilled buffer. The cells were solubilized with 100 mM NaOH containing 0.5% Triton-X100 for both liquid scintillation and Fig. 1 . Primary structure of human concentrative nucleoside transporter 1 (hCNT1) transmembrane domain 12. Homology among the protein sequences of SLC28 family (mouse, rat, human, pig, rabbit, and hagfish) demonstrates that serine in the 546 position of human CNT1 is an evolutionarily conserved residue. dry counting. The 3 H-labeled nucleosides and nucleobases were purchased from either Moravek Biochemicals or GE Healthcare. 22 Na was obtained from Perkin Elmer.
Cytotoxicity. Cytotoxicity assays were performed by seeding HeLa cells (60,000 cell/ml) in 96-well culture plates. Twenty-four hours after seeding was completed, cultures were transfected with either hCNT1 or hCNT1S546P using calcium phosphate. The transfection buffer was kept overnight and later replaced by fresh media. Twentyfour hours after the addition of fresh media, cells were exposed for 90 min to increasing concentrations (from 1 M to 6 mM) of either 5=-DFUR or cytarabine (1-␤-D-arabinofuranosylcytosine). Viability was assessed 48 h after the addition of the drugs using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. At 48 h, MTT reagent (7.5 mg/ml) was added to each well after removal of medium and incubated for 45 min at 37°C. Subsequently, the MTT reagent was discarded and the dark blue formazan crystals were solubilized in DMSO. The absorbance of formazan was measured photometrically at 595 nm using a microplate reader. The number of surviving cells is directly proportional to the quantity of the formazan product created. Data were fitted to a dose-response curve using GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA) to calculate IC 50 values.
Plasma membrane localization of hCNT1 and hCNT3 proteins. The correct localization in the plasma membrane of the various hCNT1 and hCNT3 transporter mutants was assessed by confocal microscopy.
HeLa cells cultured on glass coverslips at semiconfluence were transfected with GFP-fused chimeras. Glass coverslip-grown cells were incubated with 1 g/ml wheat germ agglutinin conjugated to tetramethylrhodamine B isothiocyanate (WGA-TRITC) for 30 min at 4°C, rinsed three times in phosphate-buffered saline-Ca 2ϩ -Mg 2ϩ , fixed for 15 min in 3% paraformaldehyde and 0.06 M sucrose, rinsed three times in phosphate-buffered saline, and then mounted with aqua-poly/mount cover-slipping medium (Polysciences, Warrington, PA). Images were obtained using a laser-scanning confocal microscope (Fluoview 500; Olympus, Tokyo, Japan).
Expression of hCNT1 and hCNT1S546P in Xenopus laevis oocytes. Human CNT1 and hCNT1S546P cDNAs were subcloned into the pBluescript vector (23) . The plasmid was linearized with XbaI and cRNA was transcribed and capped in vitro using the T3 RNA promoter (MEGAscript kit, Ambion, Austin, TX). Mature X. laevis oocytes (Xenopus Express) were injected with 50 ng of cRNA coding for each protein as previously described (1) Electrophysiology. The electrophysiology experiments were performed at room temperature using the two-electrode voltage-clamp method (1, 17) . Oocytes were perfused with Na ϩ -buffer containing (in mM): 100 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2, and 10 HEPES-Tris, pH Concentrative uptake (sodium-dependent uptake) was calculated as the transport rate in the presence of sodium minus the rate in its absence (choline medium). Data are expressed as the means Ϯ SE of three independent experiments. B: HeLa cells were transiently transfected with pEGFPC1-fused hCNT1 (top) or hCNT1S546P (bottom) and were incubated with WGA-TRITC. C: Madin-Darby canine kidney (MDCK) cells were transiently transfected with pEGFPC1-fused hCNT1 (top) or hCNT1S546P (bottom). The cells were fixed and processed for fluorescence localization on the transfected transporters as described under MATERIALS AND 7.5. External Na ϩ concentration was varied by equimolar replacement of NaCl with choline chloride. Continuous current data were recorded at a holding potential of Ϫ50 mV using Axoscope V1.1.1.14 (Molecular Devices, Sunnyvale, CA). To obtain current-voltage relations, the pulse protocol (pClamp 6, Molecular Devices) consisted of a 100-ms voltage step from a holding potential of Ϫ50 mV to a series of test potential from Ϫ50 to Ϫ150 mV in 20-mV steps. Uridine was purchased from Sigma (St. Louis, MO).
Statistical analysis. The unpaired Student's t-test was used to compare experimental data using GraphPad Prism 4 software (GraphPad Software, San Diego, CA).
RESULTS
The hCNT1Ser546Pro results from a T/C transition at position 1636 (position relative to the ATG start site based on the cDNA sequence). This serine residue appears to be localized within transmembrane domain 12 and is highly conserved among CNT orthologs (Fig. 1) . This allelic variant was initially described by Gray et al. in 2004 (14) and found at low frequency in an African American population (0.2%) but was not seen in another analysis performed by Applied Biosystems using 180 samples (including the African American population; http://www.pharmgkb.org). We also were unable to detect this variant using samples collected from two-hundred Spanish individuals. Overall, this suggests that this variant is very rare and bearing in mind that is not functional should probably be considered as a mutation. Gray and colleagues demonstrated the inability of the hCNT1Ser546Pro to transport the natural nucleoside thymidine but did not provide further insight into the impaired translocation mechanisms of this variant. Therefore, uptake measurements of a panel of 3 H-labeled natural nucleosides (uridine, cytidine, thymidine, guanosine, and adenosine) and one nucleobase (hypoxanthine) were performed in this study. As shown in Fig. 2A , the variant was not capable of translocating any hCNT1 substrate, whereas the wild type showed the typical pyrimidine-preferring substrate selectivity profile. Even after increasing the concentrations of both py- rimidine nucleosides (from 1 M to 25 mM) and sodium (from 100 to 250 mM) no hCNT1-related nucleoside transport activity was detected (data not shown).
We next investigated whether the null activity of the hCNT1S546P was due to impaired trafficking of the mutated protein to the plasma membrane. HeLa cells were transfected with GFP-fused chimeras of hCNT1 or hCNT1S546P and incubated with the plasma membrane marker WGA-TRITC. Both constructs were located predominantly at the plasma membrane (Fig. 2B) . They showed similar colocalization percentages with the plasma membrane marker as well as similar transfection rates and fluorescence intensities by flow cytometry (data not shown). Experiments run in parallel using polarized MDCK cells grown on transwell plates demonstrated that both the wild-type and the mutant transporters were correctly sorted to the apical plasma membrane (Fig.  2C) as previously it has been described for hCNT type transporters (11, 20) . However, in contrast to the wild-type protein, plasma membrane localization of hCNT1S546P did not result in increased substrate vectorial flux and cellular accumulation of natural nucleosides or nucleoside-derived drugs (Fig. 3, A and B) .
To further complement these observations, we wanted to assess the relationship between transport of nucleoside-derived analogs by the wild-type and mutated transporters and druginduced cytotoxicity. HeLa cells transfected with hCNT1, hCNT1S546P, or the empty vector pcDNA3 were exposed to increasing concentrations of 5=-DFUR (a high-affinity substrate) and cytarabine (a low-affinity substrate) for 90 min. Cell viability was measured 48 h thereafter. The IC 50 values for 5=-DFUR in HeLa cells transfected with hCNT1, hCNT1S546P, and pcDNA3 were 557 Ϯ 15.3, 745 Ϯ 15.4, and 732 Ϯ 16.1 M, respectively (Fig. 4) . The IC 50 values for cytarabine could not be calculated due to low cytotoxicity, although both assays supported the view that the hCNT1 mutant does not promote nucleoside-derived drug cytotoxicity (it does not improve the sensitivity to 5=-DFUR or cytarabine-like cells expressing hCNT1).
To gain insight into the molecular basis for the impaired function of the hCNT1S546P mutant, we performed a series of site-directed mutageneses of this residue to understand whether loss of function was due either to the presence of a proline or loss of a serine residue. In principle, a proline residue within a transmembrane domain might induce a kink in the ␣-helix, thus compromising appropriate folding and impairing function (4). The following mutants were generated and transiently expressed in HeLa cells for functional assays: hCNT1S546A, -S546C, -S546N, -S546T, and -S546 deletion. As shown in Fig. 5 , none of the mutations mediated sodium-dependent uptake of [ 3 H]uridine. Therefore, the inability to transport nucleosides and nucleoside analogues of the hCNT1S546P variant seems to be due to the specific loss of a serine residue rather than the presence of a proline in position 546. Taken together, these results suggest that Ser546 of hCNT1 seems to be important for binding and/or translocation of substrates but not for proper localization of the protein into the plasma membrane.
To gain understanding of the molecular mechanisms implicated in hCNT1S546P loss of function, we mutated the equivalent residue Ser568 in hCNT3, which is also a high-affinity concentrative nucleoside transporter but shows a stoichiometry of 2 Na ϩ ions per nucleoside translocated (33). The hCNT3S568P protein was active when transiently expressed in HeLa cells, although transport rates were significantly lower than those associated with the hCNT3 wild-type protein (Fig. 6A) . However, uptake rates of this hCNT3 mutant were similar to those shown by the hCNT1 wild-type protein (Fig. 6A) . Decreased activity compared with hCNT3 was not caused by impaired trafficking to the plasma membrane, as deduced by confocal microscopy data using a GFP-fused chimera of hCNT3S568P (Fig. 6B) . To quantify GFP-fused transporter membrane insertion, we measured colocalization with the plasma membrane marker WGA-TRITC, using Metamorph image analysis. The constructs showed similar colocalization percentages, and flow cytometry showed the same transfection rates and fluorescence intensities (data not shown). To determine whether this hCNT3 mutant showed altered substrate binding capacity, the nucleoside concentration dependence of Na ϩ -coupled uridine uptake and the sodium dependence of uridine influx mediated by either hCNT3 or hCNT3S568P were measured in transiently transfected HeLa cells (Fig. 7) . The apparent K m values for uridine were similar (5.43 Ϯ 0.43 and 5.24 Ϯ 2.33 M, for hCNT3 and hCNT3S568P, respectively, means Ϯ SE of 3 measurements), whereas the V max of the mutant was threefold lower than the wild-type (559 Ϯ 12 and 171 Ϯ 18 M, for hCNT3 and hCNT3S568P, respectively, means Ϯ SE of 3 measurements) (Fig. 7A) . The analysis of the sodium dependence of uridine influx mediated by either hCNT3 or hCNT3S568P revealed a dramatic change in the apparent K m for Na ϩ in the mutant compared with the wildtype (18.04 Ϯ 1.38 and 1.95 Ϯ 0.52 mM, for hCNT3 and hCNT3S568P, respectively, means Ϯ SE of 3 measurements) (Fig. 7B ). More importantly, the Hill coefficient of hCNT3 was significantly decreased in the mutant in a manner that would be 3 H]uridine by recombinant hCNT3, hCNT3S568P, or hCNT1 was measured in transport medium containing 137 mM NaCl or 137 mM choline chloride. Sodium-dependent transport was calculated as uptake in NaCl medium minus uptake in choline chloride. Results are expressed as means Ϯ SE of three experiments. Statistical significance was assessed using the Student's t-test (**P Ͻ 0.01). B: confocal images of fixed HeLa cells that were transfected with hCNT3S568P-pEGFPC1 and incubated with 1 g/ml WGA-TRITC for 30 min at 4°C. consistent with a shift from a 2:1 to a 1:1 (Na ϩ /nucleoside) stoichiometry (Fig. 7B, inset) .
The possibility that this residue and its equivalent in hCNT1 could be implicated in sodium binding and translocation was further analyzed by measuring 22 Na uptake rates in the presence of ouabain (thus inhibiting Na ϩ -K ϩ -ATPase) in HeLa cells transiently transfected with hCNT1 and the hCNT1S546P mutant at 6 and 12 min. 22 Na accumulation was lower in the mutant-expressing cells than in those expressing wild-type hCNT1 (6 min uptake: 56.9 Ϯ 7.0, 86.0 Ϯ 5.3, and 114.8 Ϯ 13.6 pmol/mg protein for empty vector pcDNA3, hCNT1S546P, and hCNT1, respectively. P value obtained using the Student's t-test for both pcDNA3-hCNT1S546 and pcDNA3-hCNT1 was P Ͻ 0.05; 12 min uptake: 72.1 Ϯ 3.5, 96.1 Ϯ 2.7, and 143.2 Ϯ 4.4 pmol/mg protein for empty vector pcDNA3, hCNT1S546P, and hCNT1, respectively. P value for pcDNA3-hCNT1 was P Ͻ 0.01 and P Ͻ 0.05 for pcDNA3-hCNT1S546P and hCNT1S546P-hCNT1). In addition, to better understand how the hCNT1S546P variant handles Na ϩ , the oocyte expression system was used and protein function was analyzed using the two-electrode voltage-clamp approach. A wild-type hCNT1-expressing oocyte was clamped at Ϫ50 mV and continuously perfused with Na ϩ buffer, inducing a baseline current that corresponds to the Na ϩ -leak current in the absence of substrate (Fig. 8A) (21) . The addition of 0.5 mM uridine evoked an inward current of ϳ75 nA. This current and the baseline current disappeared when the oocyte was washed out with Na ϩ -free buffer. In contrast to wild-type, hCNT1S546P failed to exhibit a noticeable uridine-induced current (Fig. 8B) , which was consistent with the absence of nucleoside uptake by the oocytes expressing the transporter (data not shown) and with the studies performed in cell lines (Figs. 2 and 3) . However, the mutantexpressing oocytes showed an uncoupled (leak) current (Fig. 8C, left) not observed in noninjected oocytes (Fig. 8C,  right) . This leak current was Na ϩ and voltage dependent, increasing with Na ϩ concentration and negative membrane potentials (Fig. 8D, left) , indicating that although this variant is unable to transport uridine, it retains the capacity for uncoupled Fig. 8 . Interaction of uridine with hCNT1 and hCNT1S546P and sodium-leak currents. A: an hCNT1-expressing oocyte was clamped at Ϫ50 mV membrane potential and perfused with Na ϩ buffer in the absence of substrate (black box), and current was continuously recorded (baseline current). The addition of 0.5 mM uridine (arrow) induced an inward current of ϳ75 nA. The oocyte was then washed out with Na ϩ -free buffer (open box), which eliminated the uridine inward current and the baseline current, and then with Na ϩ buffer until the current returned to the baseline. B: same protocol was used in an hCNT1S546P-expressing oocyte from the same batch. C: an hCNT1S546P-expressing oocyte was clamped at Ϫ50 mV membrane potential, and the current was recorded continuously while the concentration of Na ϩ in the perfusion buffer was varied as indicated (left). A similar protocol was used in a noninjected oocyte from the same batch (right). D: in another hCNT1S546P-expressing oocyte, currents at different Na ϩ concentrations were measured as a function of the membrane potential. Values were calculated as the difference between the currents obtained in the presence and absence of Na sodium transport. Wild-type leak current was saturated already at 50 mM but was also voltage dependent (21) .
DISCUSSION
Analysis of human transporter protein variants associated with altered biological activity is a suitable way to identify amino acid residues critical for function. In this study we have comprehensively analyzed the role Ser546 plays in substrate binding and translocation mediated by the high-affinity concentrative pyrimidine preferring nucleoside transporter hCNT1. This variant was initially identified by Gray et al. (14) in African-Americans but appears to be very rare, and based on its apparent allelic frequency and its profound impact on function, should be considered as a mutation rather than a polymorphic variant of the transporter protein. To date there has been no evidence for any rare inherited monogenic disease associated with mutations in SLC28 genes (the gene family encoding hCNT type proteins), although it has recently been reported that mutations in the SLC29 gene family member SLC29A3 encoding the human equilibrative nucleoside transporter 3 (hENT3) is responsible for a variety of syndromes, including H syndrome (26, 27) , pigmented hypertrichotic dermatosis with insulin-dependent diabetes (PHID) (3), and Faisalabad histiocytosis (FHC), or sinus histiocytosis with massive lymphadenopathy (SHML) (28) . Considering that the SLC28A1 S546P mutant was found in a randomly chosen apparently healthy population, it could be hypothesized that hCNT1 loss of function can be either compensated by other NT proteins or even be of minor physiological relevance unless the system is stressed.
Ser546 is a highly conserved residue in the human CNT family (SLC28 genes) but also in their corresponding orthologs. In fact, mutation of the corresponding serine residue (Ser541) into a proline in the hCNT2 isoform, which shows a 1Na ϩ /1 nucleoside stoichiometry, also resulted in loss of function (data not shown). Ser546 appears to be located within transmembrane (TM) domain 12 (14) , although the topology of CNT proteins has recently been revised and additional evidence may support a 15 TM protein structure (31) . In any case, such a position within a TM helix would anticipate that a nonconservative mutation, as the one studied here, would by itself promote loss of function and even misfolding of the protein. Nevertheless, our results suggest that the loss of the serine residue in itself promotes loss of function. This is supported by evidence that substitution of serine with other residues, such as alanine, cysteine, arginine, or threonine, similarly results in impaired biological activity. Interestingly, the putative ␣-helix wheel projection of this TM domain (Fig. 9) anticipates that the evolutionarily conserved Thr535 and Ser546 face the same side of the helix. Seryl and threonyl tandem residues in TM segments have previously been shown to play a role in sodium binding in other membrane transporters such as the ␣-subunit of the renal Na ϩ -K ϩ -ATPase, the Na ϩ /H ϩ antiporter, or the Na ϩ /I Ϫ symporter (6, 18, 30) . When we mutated Thr535 into a proline, this resulted in total loss of function (data not shown), similar to what we found in the Ser546 mutant. More importantly, loss of hCNT1 biological function was not observed when Thr535 was replaced by a serine (not shown). This could be due to the fact that in the context of a helix Thr and Ser have different properties, since the side chain of Thr is constrained to a single rotamer, whereas the hydroxyl group of Ser can adopt any of the three possible rotamers enabling the interaction. Therefore, although both serine and threonine are commonly involved in sodium binding, these results suggest that in hCNT1, Thr535 may play a structural role, whereas Ser546 is by itself relevant for appropriate substrate/cation binding and translocation. This is further reinforced by the evidence that mutation of the corresponding residue (Ser568) in hCNT3, the hCNT1 isoform showing a 2Na ϩ /1 nucleoside stoichiometry, does not result in a nonfunctional transporter, ruling out the possibility that the introduction of a proline residue in this TM domain will promote protein misfolding and impair membrane insertion. This is based on evidence that the hCNT3S568P mutant is still active [although with decreased V max values, as previously described for hCNT3S568C (35) ] and shows an unaltered apparent K m for its natural nucleoside substrates but altered sodium binding properties. Ser568 is located on the putative TM12 of hCNT3, structurally clustered in the ␣-helix moiety where many critical residues for function have been identified (32) . Ser568 is surrounded along this ␣-helix face by many accessible residues, as deduced by substitute cysteine accessibility method (SCAM) analysis, for which, in some cases, they can be substrate (uridine)-protected, either in H ϩ medium (C561, Y558) or in both Na ϩ and H ϩ media (N565, G567, I571) (31) .
Taking into consideration our findings with the hCNT1S546P variant and the functional consequences of the analogous mutation in hCNT3 (hCNT3S568P), homology modeling of hCNT1 TM12 would be consistent with Ser546 playing a major role in structuring the surrounding residues, which may significantly contribute to substrate translocation and cation coupling, similar to hCNT3. In fact, the lack of activity of the hCNT1S546P variant seems to be due to Na ϩ uncoupling in the nucleoside translocation cycle, which is probably also occurring in the hCNT3S568P mutant, thus resulting in a dramatic shift in the Hill coefficient (from 2.2 to 0.74). This fact could be interpreted as evidence for only one Na ϩ binding site being coupled to nucleoside translocation. Assuming that Na ϩ binds first to the hCNT1 transporter protein, thus inducing the appropriate conformational changes that will increase af-finity for nucleoside binding thereafter, in the hCNT1S546P mutant cation-nucleoside uncoupling appears to be severe since no substrate translocation was evident even when using very high uridine concentrations, far beyond the reported apparent K m values of natural nucleosides for hCNT1. However, despite nucleoside uncoupling, Na ϩ translocation by the hCNT1S546P protein still appears to be feasible, as deduced from both the 22 Na uptake and Na ϩ leakage measurements. In summary, in this work we have studied in depth a unique hCNT natural protein variant, hCNT1S546P, which was initially identified in African-Americans and suggested to be a nonfunctional transporter protein. Site-directed mutagenesis data demonstrate that this serine residue and likely the orientation of the hydroxyl group are essentials for function. Even though we cannot anticipate a direct role for this residue in substrate/cation binding, novel observations from this contribution, particularly based on homology modeling derived from the SCAM analysis data of the analogous TM12 of hCNT3 (31) , support the view that this TM domain and the hCNT1S546P mutant play a crucial role in cation/nucleoside coupling (although it still retains the ability to translocate Na ϩ even in the absence of nucleoside coupling). Moreover, this role may also be extended to the analogous serine residue in the hCNT3 protein isoform (Ser568) as deduced from the Hill coefficient analysis and the partial loss of function of the analogous hCNT3 mutant (hCNT3S568P).
